Pancreatic cancer clinical trial terminated

Home Research Strategic Research Program Pancreatic Cancer News Pancreatic cancer clinical trial terminated

Research in the News

Pancreatic cancer clinical trial terminated

On August 8, 2012, the pharmaceutical company Amgen announced that they will discontinue their Phase III clinical trial testing their experimental compound ganitumab (AMG 479) in combination with gemcitabine in patients with untreated metastatic pancreatic cancer. AMG 479 belongs to a category of drugs known as targeted agents, which attack a specific protein pathway thought to be important to the growth of pancreatic cancer cells.

The trial was designed to include an interim analysis that took place before the trial was officially scheduled to end, to determine whether the combination of treatments seems to be more effective than gemcitabine alone. Unfortunately, the interim data suggested that AMG 479 in combination with gemcitabine did not improve the overall survival of patients. There were no additional toxicities observed in patients treated with the combination.

Although these results are disappointing, all drugs and drug combinations must be carefully tested in a controlled clinical trial setting to determine safety and efficacy. Preliminary studies in the laboratory and trials investigating a smaller number of patients suggested that AMG 479 held promise in the treatment of pancreatic cancer. However, a larger scale Phase III trial was necessary to decide whether the drug combination was beneficial as compared to the standard treatment, gemcitabine.

It is also important to note that patients participating in clinical trials are carefully monitored and trials will be quickly stopped if patient benefit is not observed. Clinical trials that do not yield positive results lead researchers to change their focus to explore other agents that might be beneficial. Rigorous clinical trials are the only way that researchers can develop new treatment options for pancreatic cancer.

The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. For more information about ongoing clinical trials or any other questions about pancreatic cancer treatment or diagnosis, please contact a Pancreatic Cancer Action Network Patient and Liaison Services (PALS) Associate toll-free at 877-272-6226 or email pals@pancan.org. PALS Associates are available M-F 7am-5pm Pacific Time.

Click here to read Amgen’s press release.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.





shop purple logo

Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.